Navigation Links
Clinical Results for Oramed's Oral Diabetes Treatment Published in Peer Reviewed Journal PLOS ONE
Date:5/1/2013

JERUSALEM, May 1, 2013 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral delivery systems of drugs currently administered by injection, announced today that its article titled, "Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled Type 1 diabetes: a pilot study," has been published in PLOS ONE, an international, peer-reviewed, open-access journal which covers primary scientific and medical research.

The article details the results of a clinical study, in which ORMD-0801 was administered to patients with unstable Type 1 diabetes, in conjunction with their regular anti-diabetes treatment regimens.  These patients typically suffer from unpredictable and frequent swings in their blood sugar levels, which often demand hospitalization and severely disrupt their quality of life. The addition of ORMD-0801 was well tolerated and significantly stabilized blood sugar levels in this patient group. A significant drop in the frequency of above-normal blood sugar readings was observed, as well as a decrease in overall blood sugar levels throughout the day.  

"These published results lay the groundwork for further study of the potential of ORMD-0810 as a treatment that can considerably aid a patient population resistant to standard anti-diabetes treatment protocols," stated Oramed CEO Nadav Kidron .

The article can be viewed on PLOS ONE's site, the content of which is not part of this press release, at: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0059524

About Oramed Pharmaceuticals  

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently approaching Phase 2 clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), currently approaching Phase 2a trials. The company's corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release, please visit  http://www.oramed.com.

The company's fact sheet, the content of which is not part of this press release, can be viewed here.

Forward-looking statements: This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, we are using forward-looking statements when we discuss the potential of ORMD-0810 as a treatment that can considerably aid a patient population resistant to standard anti-diabetes treatment protocols or our oral insulin and oral exenatide candidates approaching Phase 2 clinical trials and 2a clinical trials, respectively. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.

Company Contact:
Oramed Pharmaceuticals
Aviva Sherman
Cell: +972-54-792-4438
Office: +972-2-566-0001       
Email: aviva@oramed.com 


'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Acutus Medical, Inc. Initiates "First-In-Man" Clinical Study of Real-Time 3D Imaging Catheter with CT/MRI Quality
2. Rush University Medical Center Presents Positive MuGard Clinical Data at the Oncology Nursing Society 38th Annual Congress
3. Oramed Pharmaceuticals to Present Results of its Key Clinical Studies of Oral Insulin in Type 1 Diabetes Patients at the GTC Diabetes Summit, Boston, MA; April 29-30, 2013
4. Cannabis Science announces preclinical development program for CS-TATI-I, commencing EU operations in the Netherlands and sourcing proprietary material for pharmacokinetic characterization
5. Elekta to Highlight Clinical and Safety Advantages of Gamma Knife Radiosurgery at 2013 AANS Meeting
6. Anterios, Inc., Announces Corporate Financing To Further Clinical Development Of Its Topical Botulinum Product
7. Top-line Data Show AcelRx Pharmaceuticals ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial
8. ISIS Pharmaceuticals Initiates a Clinical Study of ISIS-SMN Rx in Infants With Spinal Muscular Atrophy
9. Statement from the Cystic Fibrosis Foundation on Promising Phase 2 Clinical Trial Results of Kalydeco and VX-661 (Vertex Pharmaceuticals Inc.)
10. Omeros to Present Additional OMS302 Clinical Data at the Annual ASCRS and ASOA Symposium and Congress
11. Savara Pharmaceuticals Initiates Phase 2 Clinical Trial of AeroVanc for MRSA Lung Infection in Cystic Fibrosis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... 11, 2017  True Health, a leader in ... effort during National Breast Cancer Awareness month to ... Research recently ... that more than 10 million American women are ... BRCA1 or BRCA2 and have not had testing. These ...
(Date:10/5/2017)... , Oct. 5, 2017  In response ... of Oral and Maxillofacial Surgeons (AAOMS) released prescribing ... – to be used as a first-line therapy ... Recognizing the ... AAOMS White Paper "Opioid Prescribing: Acute and Postoperative ...
(Date:10/2/2017)... Lilly and Company (NYSE: LLY ) will ... 2017 on Tuesday, October 24, 2017. Lilly will also ... investment community and media to further detail the company,s ... at 9 a.m. Eastern time. Investors, media and the ... conference call through a link that will be posted ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Dickinson Insurance and ... and financial preparation services, is providing an update on a charitable event that ... City Rescue is a locally recognized nonprofit that provides shelter and care for ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The American ... to become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer ... Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. ...
(Date:10/13/2017)... Ill. (PRWEB) , ... October ... ... Edwardsville School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer ... healthcare professionals on guideline updates for the primary prevention of cardiovascular diseases ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... ... , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many ... event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids ... of all ages; it is a non-competitive, non-timed event, which is all about having ...
Breaking Medicine News(10 mins):